VIDEO: JAK inhibitors may help improve quality of life in myeloproliferative neoplasms

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Yeah, so that's a very important question. That's a very important point, so remember I told you MPNs are chronic myeloid malignancies, which means that these are diagnoses, these are conditions that are going to evolve over months, over years in a patient's lifespan. And constitutional symptoms is a major feature of myelofibrosis of MPNs. And to have something be affecting your life day to day and impacting your quality of life for years together is something that is very important to address, which is why the role of JAK inhibitors is so critical, because they do have a role in improving quality of life by improving the constitutional symptoms.

The importance of symptom burden, the importance of quality of life in myelofibrosis is evident also from even the MPN total symptom score or MPN symptom assessment form that has been developed over the last decade, which is probably one of the first malignancies to find its way into in terms of being captured on a regular basis and being the metric of drug approval. As you may know, symptom assessments are commonly either a co-primary endpoint or a key secondary endpoint for most of the clinical trials when new drugs are being evaluated in this diagnosis. The relevance and the importance of this cannot be overstated in my opinion, this being a chronic myeloid malignancy and symptoms being a major part of the complex of myelofibrosis.